Biology Reference
In-Depth Information
Drusano GL, Stein DS. 1998. Mathematical modeling of the interrelationship of CD4 lymphocyte
count and viral load changes induced by protease inhibitor indinavir. Antimicrob Agents Che-
mother 42: 358±361.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K,
Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF,
1997. Identi®cation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
Science 278: 1295±1300.
Finzi D, Blankson J, Siliciano JD, et al. 1999. Latent infection of CD4
T cells provides a mecha-
nism for lifelong persistence of HIV-1, even in patients on e¨ective combination therapy. Nat
Med 5: 512±517.
Fleury S, de Boer RB, Rizzardi GP, Wolthers KC, Otto SA, Welbon CC, Grasiozi C, Knabenhans
C, Soudeyns H, Bart PA, Gallant S, Corpataux JM, Gillet M, Meylan P, Schnyder P, Meuwly
JY, Spreen W, Glauser M, Miedema F, Pantaleo G. 1998. Limited CD4
T cell renewal in early
HIV-1 infection: E¨ect of highly active antiretroviral therapy. Nat Med 4: 794±801.
Fleury S, Rizzardi GP, Chapuis A, Tambussi G, Knabenhans C, Simeoni E, Meuwly J, Corpataux
J, Lazzarin A, Miedema F, Pantaleo G. 2000. Long-term kinetics of T cell production in HIV-
infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci USA 97:
5393±5398.
Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, Telenti A, Vernazza PL,
Rickenbach M, Flepp M, Malinverni R. 1999. Discontinuation of primary prophylaxis against
Pneumocystis
carinii
pneumonia
in
HIV-1-infected
adults
treated
with
combination
anti-
retroviral therapy. Swiss HIV Cohort Study. N Engl J Med 340: 1301±1306.
Gilquin J, Piketty C, Thomas U, et al. 1997. Acute cytomegalovirus infection in AIDS patients with
CD4 counts above 100 10
6
cells/l following combination anti-retroviral therapy including
protease inhibitors. AIDS 11: 1659±1660.
Giorgi JV, Fahey JL, Smith DC, Hultin LE, Cheng HL, Mitsuyasu RT, Detels R. 1987. Early
e¨ects of HIV on CD4 lymphocytes in vivo. J Immunol 138: 3725±3730.
Goh LE, Mcdade H, Kinloch S, Perrin L, Cooper D, Phillips A, Hoen B, Autran B, Sonnerborts A,
Tsoukas C. 2000. The QUEST trial, a paradigm of HIV collaborative research. Nat Med 6:
1194.
Gorochov G, Neumann AU, Kereveur A, Parizot C, Li TS, Katlama C, Karmochkine M, Raguin
G, Autran B, Debre P. 1998. Perturbation of CD4 and CD8 T cell repertoires during progres-
sion to AIDS and in¯uence of antiviral therapy. Nat Med 4: 215±221.
Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. 2000.
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic re-
sponse after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401±410.
Grassi F, Hosmalin A, Mcilroy D, Calvez V, Debre P, Autran B. 1999. Depletion in blood CD11c-
positive dendritic cells from HIV-infected patients. AIDS 13: 7841.
Gray CM, Lawrence J, Schapiro JM, Altman JD, Winters MA, Crompton M, Loi M, Kundu SK,
Davis MM, Merigan TC. 1999. Frequency of class I HLA-restricted anti-HIV CD8
T cells in
individuals receiving highly active antiretroviral therapy (HAART). J Immunol 162: 1780±1788.
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. 1997. Treatment with
indinavir, zidovudine, and lamivudine in adults with human immunode®ciency virus infection
and prior antiretroviral therapy. N Engl J Med 337: 734±739.
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg
JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA and the ACTG 320 Study Team.
1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human im-
munode®ciency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J
Med 337: 725±739.
Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borle¨s JC, Boucher CA, Coutinho
RA, Lange JM, Rinke de Wit TF, Tsegaye A, van Dongen JJ, Hamann D, de Boer RJ, Mie-
